N/A N=120 Impact of Treatment With ALVEOGYL in Patients With Post-extraction Dry Socket
Dry Socket
Primary: Pain Using a Visual Analog Scale (VAS : 0-10) — 106; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=16 Clinical and Histological Evaluation of Deproteinizated Bovine Bone Allograft and Lyophilized Equine Bone Allograft for Sinus Lift.
Maxillary Sinus Floor Augmentation
Primary: Histomorphometric Evaluation of New Bone Formation. — 22.20; 22.84; 50.77; 46.20 percentage of millimeters
Phase 2 N=138 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment — 28.6; 29.3; 32.0 mmHg — p=0.1688
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
N/A N=51 CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation
Alveolar Ridge Defect
Primary: Change in Horizontal Ridge Widths From Baseline to 6 Months — 2.61 mm
N/A N=199 Alvopem® (Pemetrexed) Safety Assessment
Non Small Cell Lung Cancer · Malignant Pleural Mesothelioma
Primary: Safety Assessment Including Treatment-related Adverse Events (Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE))…
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 3 N=34 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
Alpha1-antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution — 0; 0 Participants
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
Phase 2 N=15 COVID-19 Study of Safety and Tolerability of Alvelestat
Covid19
Primary: Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event — 3; 5 Participants
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Phase 2 N=72 Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Change in Free Elastase in Induced Sputum From Baseline to Week 4 — -7.42; 6.11 ug/mL — p=0.197
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
N/A N=207 Autologous Stem Cell Treatment for Chronic Lung Disease Study
COPD · Interstitial Lung Disease
Primary: Change in FEV1 From Baseline Among COPD Patients — 12.8 percentage of change in FEV1
Phase 2 N=18 Biomarkers of Irritant-Induced and Allergic Asthma
Asthma
Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
Phase 2 N=36 Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"
Alpha-1 Antitrypsin Deficiency
Primary: Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF) — 4551.023; 13454.772; -27.15 nmol — p=0.0005
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 2 N=22 Bone Material Comparison in Maxillary Sinus Augmentation
Alveolar Bone Resorption · Sequela · Tooth Extrusion
Primary: Bone Density - Limited View CBCT (Cone-beam Computed Tomography) Measurements — 14.4; 1.5 percentage of bone height shrinkage
N/A N=37 The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges
Alveolar Ridge Augmentation · Alveolar Ridge Preservation
Primary: New Bone Formation (in %) With the Use of Small vs. Large Particle Bone Allografts — 17.3; 25.9; 41.0; 31.4 % of new bone
Phase 3 N=26 Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot
Alveolar Bone Loss · Tooth Loss
Primary: Overall Horizontal Change in Alveolar Ridge Width — -1.34; -2.21 Millimeters
Phase 4 N=40 The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant
Chronic Sinusitis, Ethmoidal
Primary: Inflammation Score — 26.7; 26.8; 21.5; 17.6 units on a scale — p=0.4709
Phase 2 N=9 Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug. — 1; 1; 0; 2 Participants
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 4 N=17 Treatment of Post-Extraction Dehisced Socket - A Case Series Study
Tooth Loss
Primary: Bone Volumetric Reduction From Baseline to 20 Weeks Post-extraction — 73.26 mm3
Phase 2 N=13 Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Interdental Papillary Insufficiency
Primary: Number of Responders Based on the Average Investigator Evaluation of Change From Baseline for All Treated Areas on the Global Ordinal Rating Scale (GORS) — 10 participants
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area